No Data
No Data
Esperion to Report Second Quarter 2024 Financial Results on August 12
Esperion to Participate in Upcoming BTIG Biotech Conference
New Digital First Marketing Campaign From Esperion Alerts Patients With Uncontrolled LDL Cholesterol to the "Lipid Lurkers" Inside Their Arteries
Notable Analyst Calls This Week: Nike, Micron and FedEx Among Top Picks
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
No Data